|
March
26, 2007--Eli Lilly has announced a $150 million
expansion of its Lilly Centre for Systems Biology (LSB) in
Singapore. The
project is a partnership with the Singapore Economic
Development Board (EDB).
The facility became operational in November 2002,
and Lilly reports “the Centre has discovered multiple
biomarkers which are supporting Lilly clinical trials
worldwide” according to a press release.
The expansion is scheduled to take place over five
years.
The
release also says that several information technology
tools and platforms for drug discovery have been developed
at the LSB, and that the Centre has collaborations with
the Genomics Institute of Singapore, the Broad Institute
in Boston, and the Translational Genomics (TGEN) Research
Institute in Phoenix, Arizona.
Lilly’s
first facility in Singapore was the Lilly-NUS Centre for Clinical
Pharmacology – a joint venture with the National
University of Singapore and the EDB.
To date, that site has performed more than 100
clinical trials, including trials that involve
pharmacogenomic stratification, according to the company.
For
more information, see the company
press release. |
